Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 19

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 19
---
 |
| Working capital(3)                               |     |                                      |  133,859 |   |     |          |  133,859 |   |     |              |  308,826 |   |
| Total assets                                     |     |                                      |  197,265 |   |     |          |  197,265 |   |     |              |  369,461 |   |
| Total liabilities                                |     |                                      |   15,446 |   |     |          |   15,446 |   |     |              |   14,595 |   |
| Convertible preferred stock                      |     |                                      |  330,368 |   |     |          |        — |   |     |              |        — |   |
| Accumulated deficit                              |     |                                      | (165,238 | ) |     |          | (165,238 | ) |     |              | (165,238 | ) |
| Total stockholders’ (deficit) equity             |     |                                      | (148,549 | ) |     |          |  181,819 |   |     |              |  354,866 |   |

| (1) | Pro forma amounts give effect to the automatic conversion of all outstanding shares of our convertible preferred stock                                                                                                      
 into an aggregate of 27,149,206 shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity immediately prior to the closing of this offering. |

| (2) | Pro forma as adjusted amounts give effect to (i) the pro forma adjustments set forth in footnote (1) above and                                                                                                                                       
 (ii) the issuance and sale of 10,588,233 shares of our common stock in this offering at the initial public offering price of $18.00 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by 
 us.                                                                                                                                                                                                                                                  |

| (3) | We define working capital as current assets less current liabilities. See our consolidated financial statements and the       
 related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. |

16

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as the other information in this prospectus, including our audited consolidated financial statements and the related notes appearing elsewhere in